Shares in Zeneca sent 35p higher on Roche bid rumours
Saturday 12 April 1997
The bid rumour, the latest in a long series, emerged in a report in a Swiss newspaper which suggested that an offer worth pounds 21 to pounds 22 a share would be launched by Roche early next week. Cash, a weekly financial publication, claimed the two companies were in talks and the Basle-based Roche planned to sell off Zeneca's agrochemicals and specialty chemicals operations, keeping only the drugs business.
Neither company would comment yesterday. A representative for Roche said: "We've heard the rumours before and we didn't comment then and we are not commenting now."
The Swiss company has substantial cash resources and is thought to be interested in making acquisitions, but analysts played down the latest twist to what has become a long-running saga. James Dodwell, a pharmaceuticals watcher at Barclays de Zoete Wedd, said the two companies would fit together reasonably well. Roche had a lot of hospital products, while Zeneca's portfolio was strong in drugs targeted at GPs. Zeneca also had a strong franchise in cancer treatments, which Roche lacked, he suggested.
But he said: "Zeneca won't go freely. They want to remain independent and have said they are going to achieve 15 per cent per annum earnings growth for the next five years." Even for Roche, the possible $35bn price tag for the British group would be hard to digest, while the rating might be hard to justify.
The one piece of tangible good news yesterday for Zeneca, headed by chief executive Sir David Barnes, was that a US appeal court had upheld its patent rights over Nolvadex, still the most widely used treatment for breast cancer nearly quarter of a century after its launch. The appeal to the Federal court followed a challenge by Novopharm, a Canadian maker of generic drugs, which had been thrown out by a lower court in Maryland last April. Zeneca said the decision disposed of the proceedings instituted by Novopharm, which had wanted to produce a generic form of the drug.
The decision helps protect Zeneca's US patent until its expiry in 2002, although the company said it would continue patent infringement proceedings against two other companies, Mylan Pharmaceuticals and Pharmachemie, which have submitted applications for generic forms of the drug with America's Food and Drug Administration.
- 1 If these extraordinarily powerful images of a dead Syrian child washed up on a beach don't change Europe's attitude to refugees, what will?
- 2 Senior British politicians tell David Cameron: When dead children are being washed up on beaches – it's time to act
- 3 Make your voice heard: Sign The Independent's petition to welcome refugees
- 4 Refugee crisis: Aylan's life was full of fear - in death, he is part of 'humanity washed ashore'
- 5 German police forced to ask public to stop bringing donations for refugees arriving by train
Senior British politicians tell David Cameron: When dead children are being washed up on beaches – it's time to act
Jeremy Corbyn calls Osama bin Laden's killing a 'tragedy' - but was it taken out of context?
If these extraordinarily powerful images of a dead Syrian child washed up on a beach don't change Europe's attitude to refugees, what will?
Britain to take more refugees as Cameron bows to pressure after more than 100,000 back our campaign
If you're not already angry about the refugee crisis, here's a history lesson to remind you why you really should be
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
iJobs Money & Business
£20000 - £40000 per annum + OTE + Incentives + Benefits: SThree: Established f...
£20000 - £25000 per annum + OTE 40/45k + INCENTIVES + BENEFITS: SThree: The su...
£14000 - £16000 per annum: Recruitment Genius: This company was established in...
£20000 - £25000 per annum + OTE 40k: SThree: SThree are a global FTSE 250 busi...